Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR) with anti-cancer activity in multiple tumor types, including renal cell carcinoma (RCC), mantle cell lymphoma, breast cancer, and well-differentiated NENs. Here, MTOR is linked to cancer.